Genetic Analysis of Subjects Enrolled in the FSGS - Controlled Trial
| Main study | Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis: Phase II Clinical Trial |
|---|---|
| Contact name | Jeffrey Kopp |
| Contact phone | 301-594-3403 |
| Contact email | jeffreyk@intra.niddk.nih.gov |
| PI name | Jeffrey Kopp |